ArticleThe journal of nutrition, health & aging2026
Association of plasma growth differentiation factor 15 with wake after sleep onset in mild cognitive impairment.
Article in The journal of nutrition, health & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCirculating growth differentiation factor 15 (GDF-15) concentrations increase with age and are elevated in chronic diseases, but evidence regarding habitual wake after sleep onset (WASO) and circulating GDF-15 remains limited. We therefore examined the cross-sectional association between plasma GDF-15 and wearable-estimated WASO in older adults with mild cognitive impairment (MCI).
designCross-sectional biomarker analysis of first-year data from a prospective community-based cohort.
settingUSUKI study, Usuki, Oita, Japan.
participants118 community-dwelling adults aged ≥65 years with MCI.
interventionNone. MEASUREMENTS: We measured plasma GDF-15 concentrations using an enzyme-linked immunosorbent assay. We averaged wearable sleep data across repeated assessments. WASO was the primary measure of sleep continuity; total sleep time (TST) was examined as a measure of sleep quantity; and amyloid burden was assessed using
resultsThe median plasma GDF-15 concentration was 1,230.8 pg/mL (IQR, 956.6-1,590.5), and the median WASO was 18.4 min (IQR, 11.6-27.5). After adjustment for age, sex, education, diabetes mellitus, and estimated glomerular filtration rate, each 10-min increment in WASO was associated with a 10.6% higher GDF-15 concentration (95% CI, 4.8%-16.8%; p < 0.001). TST and PiB-PET global SUVR were not significantly associated with GDF-15, and the proportion of PiB-positive participants did not differ across GDF-15 tertiles.
conclusionIn older adults with MCI, poorer habitual nocturnal sleep continuity, as reflected by greater wearable-estimated WASO, was associated with higher plasma GDF-15 concentrations after multivariable adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.